The application period has now closed. Apply today to join survivors, caregivers and activists across the country to affect change for those impacted by ovarian cancer. Advocate Leaders will learn how to … Continued
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” … Continued
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic … Continued
Dear Friends, I hope this finds you all well, staying safe, and enjoying preparations for a lovely holiday. Whether you’re gathering with loved ones or holding them in your heart as … Continued
As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and … Continued
Clinical trials are fundamental to the discovery of new and better therapies in the fight against ovarian cancer. Yet enrollment and widespread availability remain a challenge. To address both financial … Continued
The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a … Continued
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still … Continued
November 15-16, 2021 | Register Today! Are you passionate about issues affecting the ovarian cancer community? Now is your chance to have your voice heard at the highest levels — … Continued
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news … Continued
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in … Continued
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to … Continued
Get email updates about research news, action alerts, and ways to join the fight.
